In 2004, Genzyme established a commercial oncology franchise to provide comprehensive cancer care from diagnostics to therapeutics to follow-up monitoring.

Thyrogen is currently an important adjunct to thyroid cancer therapy because it can lead to earlier detection of recurrence and prevent deaths from this highly treatable disease. Becoming the standard of care, Thyrogen grew nearly 50 percent in 2004, with a dedicated sales force and growing commercial infrastructure. We have also completed a successful study of Thyrogen in remnant ablation following thyroid cancer surgery and filed for regulatory approval. The European Union approved this indication in the first quarter of 2005, and we anticipate U.S. approval later in the year. There are about 35,000 thyroid remnant ablation procedures each year in the United States and Europe, and we estimate that Thyrogen has the potential to be used by up to 80 percent of these patients.